AgingResearch.NewsJoin free

SLC25A13-K568 acetylation

There is 1 paper on SLC25A13-K568 acetylation in aging research: none in people yet, 1 in cells. The newest story, Oct 31, 2026: “Protein loss curbs colorectal cancer in experiments”.

Biomarker

1 paper studies it2 findings

1 new paper in 30 daysSee all 1

“Clinically, low levels of SLC25A13-K568 acetylation are associated with poor prognosis in human CRC.”
SIRT3 deficiency triggers mitochondrial dysfunction-associated senescence to suppress colorectal cancer progression via SLC25A13 acetylationOncogene2026doi:10.1038/s41388-026-04037-8
  • Cells1

Upstream

1

SIRT3

downin human cells1

1 study

  1. SIRT3 decreases SLC25A13-K568 acetylation in human cells.

    “SIRT3 deacetylates the mitochondrial carrier SLC25A13 at lysine 568.”

    Cells

    Protein loss curbs colorectal cancer in experiments

    Oncogene

More on SIRT3

Associations

1

Poor colorectal cancer prognosis

mixedin humans1

1 study

  1. SLC25A13-K568 acetylation is associated with poor colorectal cancer prognosis in humans (low SLC25A13-K568 acetylation in colorectal cancer).

    “Clinically, low levels of SLC25A13-K568 acetylation are associated with poor prognosis in human CRC.”

    Humanslow SLC25A13-K568 acetylation in colorectal cancer

    Protein loss curbs colorectal cancer in experiments

    Oncogene

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 01 paper in 12 months
Oncogene

Protein loss curbs colorectal cancer in experiments

Experiments found that losing a mitochondrial regulator induced a state in which cells stop dividing and suppressed colorectal cancer progression.Experiments found that losing a mitochondrial regulator induced a state in which cells stop dividing and suppressed colorectal cancer progression.

Experiments in cellsMechanisms
Paper

Related